{"id":"da-8159","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, DA-8159 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"DA-8159 is a small molecule that acts as a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:30:54.633Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT03013751","phase":"PHASE3","title":"A Extension Study of Udenafil in Adolescents","status":"COMPLETED","sponsor":"Mezzion Pharma Co. Ltd","startDate":"2017-02-06","conditions":"Functional Single Ventricle Heart Disease","enrollment":301},{"nctId":"NCT05918211","phase":"PHASE3","title":"Fontan Udenafil Exercise Longitudinal Assessment Trial - 2","status":"RECRUITING","sponsor":"Mezzion Pharma Co. Ltd","startDate":"2023-10-30","conditions":"Single Ventricle Heart Disease","enrollment":436},{"nctId":"NCT03430583","phase":"PHASE3","title":"Evaluation of Fontan-associated Hepatic Stiffness and the Efficacy of Udenafil in Reducing Liver Stiffness","status":"COMPLETED","sponsor":"Mezzion Pharma Co. Ltd","startDate":"2018-02-20","conditions":"Single Ventricle Heart Disease","enrollment":88},{"nctId":"NCT02741115","phase":"PHASE3","title":"Fontan Udenafil Exercise Longitudinal Assessment Trial","status":"COMPLETED","sponsor":"Mezzion Pharma Co. Ltd","startDate":"2016-07-22","conditions":"Single Ventricle Heart Disease","enrollment":400},{"nctId":"NCT02201342","phase":"PHASE1, PHASE2","title":"Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents","status":"COMPLETED","sponsor":"Mezzion Pharma Co. Ltd","startDate":"2014-07","conditions":"Single Ventricle Heart Disease After Fontan Surgery","enrollment":36},{"nctId":"NCT01108900","phase":"","title":"A Study Of The Evaluation Of Patients Opulation With Erectile Dysfunction, Treated With Sildenafil","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2010-07","conditions":"Erectile Dysfunction","enrollment":100},{"nctId":"NCT03142542","phase":"PHASE4","title":"The Efficacy and Safety of Udenafil in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2017-05","conditions":"Prostate Cancer With Radical Prostatectomy","enrollment":99},{"nctId":"NCT01553721","phase":"PHASE2","title":"Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2011-08","conditions":"Pulmonary Arterial Hypertension","enrollment":63},{"nctId":"NCT02304198","phase":"PHASE2, PHASE3","title":"Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2014-04","conditions":"Pulmonary Arterial Hypertension","enrollment":59},{"nctId":"NCT01967251","phase":"PHASE2","title":"Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2015-09","conditions":"Erectile Dysfunction, Benign Prostatic Hyperplasia","enrollment":""},{"nctId":"NCT01037218","phase":"PHASE3","title":"Treatment of Erectile Dysfunction II","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2009-09","conditions":"Erectile Dysfunction","enrollment":601},{"nctId":"NCT01065012","phase":"PHASE3","title":"Treatment of Erectile Dysfunction - Long Term Safety and Efficacy","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2010-01","conditions":"Erectile Dysfunction","enrollment":1027},{"nctId":"NCT01421940","phase":"PHASE4","title":"The Efficacy of Penile Rehabilitation Using Udenafil After Total Mesorectal Excision of Rectal Cancer","status":"COMPLETED","sponsor":"Kyungpook National University Hospital","startDate":"2009-10","conditions":"Rectal Cancer","enrollment":80},{"nctId":"NCT01232010","phase":"PHASE1","title":"Clinical Study to Investigate the Safety and Pharmacokinetics of SK3530 Tablet in Renal Impaired Male Patients","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2009-11","conditions":"Renal Insufficiency, Kidney Diseases, Urologic Diseases","enrollment":12},{"nctId":"NCT01646515","phase":"PHASE3","title":"Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Chronic Systolic Heart Failure","status":"TERMINATED","sponsor":"Seoul National University Hospital","startDate":"2011-12","conditions":"Systolic Heart Failure","enrollment":41},{"nctId":"NCT01769482","phase":"PHASE4","title":"Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2011-12","conditions":"Microvascular Angina","enrollment":70},{"nctId":"NCT01929213","phase":"PHASE1","title":"Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Bosentan After Oral Administration","status":"UNKNOWN","sponsor":"Dong-A Pharmaceutical Co., Ltd.","startDate":"2013-08","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT01967264","phase":"PHASE1","title":"Safety and Pharmacokinetic Profile of Udenafil in Healthy Mexican Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-07","conditions":"Erectile Dysfunction, Phosphodiesterase 5 Inhibitor","enrollment":83},{"nctId":"NCT01940952","phase":"PHASE3","title":"Zydena on Cognitive Function of Alzheimer's Disease Patients","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2013-09","conditions":"Alzheimer's Disease","enrollment":210},{"nctId":"NCT01928563","phase":"PHASE1","title":"Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine","status":"UNKNOWN","sponsor":"Dong-A Pharmaceutical Co., Ltd.","startDate":"2013-09","conditions":"Healthy Male Subjects","enrollment":24},{"nctId":"NCT01901640","phase":"PHASE3","title":"Safety Study of Once-a-Day Dosing of Udenafil to Treat Erectile Dysfunction","status":"COMPLETED","sponsor":"Dong-A Pharmaceutical Co., Ltd.","startDate":"2011-11","conditions":"Erectile Dysfunction","enrollment":302},{"nctId":"NCT01696240","phase":"PHASE3","title":"A Randomized Trial of Udenafil Therapy in Patients With Mild Pulmonary Hypertension [ULTIMATE-Mild PHT]","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2012-09","conditions":"Mild Pulmonary Hypertension","enrollment":40},{"nctId":"NCT01599117","phase":"PHASE3","title":"A Randomized Trial of Udenafil Therapy in Patients With Heart Failure With Preserved Ejection Fraction [ULTIMATE-HFpEF]","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2012-10","conditions":"Diastolic Heart Failure","enrollment":52},{"nctId":"NCT01774864","phase":"PHASE3","title":"Efficacy and Safety Study of Udenafil to Treat Erectile Dysfunction","status":"COMPLETED","sponsor":"Dong-A Pharmaceutical Co., Ltd.","startDate":"2011-04","conditions":"Erectile Dysfunction","enrollment":349},{"nctId":"NCT01280266","phase":"PHASE2, PHASE3","title":"Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2011-01","conditions":"Raynaud Phenomenon","enrollment":29},{"nctId":"NCT00956306","phase":"PHASE1","title":"A Pharmacokinetic Study of Udenafil in Adult Subjects With or Without Impaired Hepatic Function","status":"COMPLETED","sponsor":"Dong-A Pharmaceutical Co., Ltd.","startDate":"2007-11","conditions":"Hepatic Impairment","enrollment":18},{"nctId":"NCT00607282","phase":"PHASE2","title":"Efficacy of Udenafil After Radical Resection for Sigmoid Colon and Rectal Cancer","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2009-03","conditions":"Erectile Dysfunction, Sigmoid Colon Cancer, Rectal Cancer","enrollment":46},{"nctId":"NCT01305083","phase":"PHASE3","title":"Efficacy and Safety Study of Udenafil Tablets in Erectile Dysfunction.","status":"COMPLETED","sponsor":"Abdi Ibrahim Ilac San. ve Tic A.S.","startDate":"2010-10","conditions":"Erectile Dysfunction","enrollment":118},{"nctId":"NCT01037244","phase":"PHASE3","title":"Treatment of Erectile Dysfunction I","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2009-09","conditions":"Erectile Dysfunction","enrollment":618},{"nctId":"NCT01230541","phase":"PHASE1","title":"Effect of Udenafil on Spermatogenesis","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2010-09","conditions":"Spermatogenesis, Erectile Dysfunction","enrollment":239},{"nctId":"NCT01466543","phase":"PHASE2","title":"Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2011-11","conditions":"Vascular Dementia, Subcortical Vascular Dementia","enrollment":80},{"nctId":"NCT01364181","phase":"PHASE3","title":"The Impact of Udenafil on Exercise Capacity in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2010-03","conditions":"Dyspnea, Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension","enrollment":23},{"nctId":"NCT01241032","phase":"PHASE1","title":"Phase I Study to Investigate the Alcohol Interaction of DA8159","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2006-06","conditions":"Healthy Volunteers, Erectile Dysfunction","enrollment":24},{"nctId":"NCT01231997","phase":"PHASE1","title":"Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2009-11","conditions":"Renal Insufficiency, Kidney Diseases, Urologic Diseases","enrollment":27},{"nctId":"NCT00767598","phase":"PHASE1","title":"The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors in Male Subjects","status":"COMPLETED","sponsor":"Inje University","startDate":"2007-12","conditions":"Pharmacokinetics of Three PDE5Is, Healthy Subjects, Genetic Polymorphic CYP3A5","enrollment":21},{"nctId":"NCT00282607","phase":"PHASE2","title":"A Study of DA-8159 in Subjects With Erectile Dysfunction","status":"COMPLETED","sponsor":"Dong-A PharmTech Co., Ltd.","startDate":"2005-05","conditions":"Erectile Dysfunction","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":48,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DA-8159","genericName":"DA-8159","companyName":"Dong-A PharmTech Co., Ltd.","companyId":"dong-a-pharmtech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DA-8159 is a small molecule that acts as a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}